Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Ovarian Cancer
- Sponsor
- Tempus AI
- Enrollment
- 1000
- Locations
- 2
- Primary Endpoint
- Create robust data set of health information
- Status
- Active, Not Recruiting
- Last Updated
- 12 months ago
Overview
Brief Summary
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Detailed Description
The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Solid or hematologic malignancy.
- •Willing and able to provide informed consent where required.
- •Has received or will receive genomic profiling.
Exclusion Criteria
- •Individuals without the capacity to consent.
- •Prisoners at the time of enrollment.
Outcomes
Primary Outcomes
Create robust data set of health information
Time Frame: Up to 10 years
To create a robust data set of health information about cancer patients who receive comprehensive genomic profiling in order to facilitate future novel precision medicine research
Secondary Outcomes
- Evaluate longitudinal paired tissue and cell free molecular testing(Up to 10 years)
- Document clinical events for patients who have had comprehensive genomic profiling(Up to 10 years)